ISSN 2756-3707
International Journal of Histology and Cytology ISSN 2447-9535 Vol. 3 (7), pp. 270-273, July, 2016. © International Scholars Journals
Full Length Research Paper
Impact of intracoronary autologous bone marrow mononuclear cells in patients with dilated cardiomyopathy
P. L. N Kaparthi1*, Gupta Namita2, Lakshmi K. Chelluri2, V. Surya Prakasa Rao1, P. Kantilal Shah1, Adavi Vasantha2, S. Kamaraju Ratnakar2 and K. Ravindhranath1
1Department of Cardiology, Global Hospitals, Lakdi-ka-Pool, Hyderabad –500 004 (A.P), India.
2Department of Transplant Biology and Stem Cell, Global Hospitals, Lakdi-ka-Pool, Hyderabad –500 004 (A.P), India.
*Corresponding author: E-mail: [email protected]. Tel: 9848047521. Fax: 0091-40-2324 4455.
Accepted 05 February, 2016
Abstract
The impact of intracoronary autologous bone marrow mononuclear cells (BMMC) in patients with DCM (dilated cardiomyopathy) with severe left ventricular (LV) dysfunction was assessed. The study included five DCM patients (age group 20 - 65 years) with ejection fraction (EF) of ≤ 30%. Mononuclear cells (Mean MNC count: 9.16 x 107 and Mean CD34 positive cell count: 3.68 x 105) were infused through intracoronary injection into the patients. Left ventricular ejection fraction (LVEF) was increased from 25 30% to 40 - 45% (approximately 500,000 CD34 + cells) in two of the patients. Conclusively, bone marrow mononuclear cell therapy has a potential to be considered a standard therapeutic entity for the treatment of dilated cardiomyopathy with severe LV dysfunction.
Key words: Mononuclear cells, dilated cardiomyopathy, autologous, intra-coronary.